Hepatocellular carcinoma in the thalassaemia syndromes

被引:136
作者
Borgna-Pignatti, C
Vergine, G
Lombardo, T
Cappellini, MD
Cianciulli, P
Maggio, A
Renda, D
Lai, ME
Mandas, A
Forni, G
Piga, A
Bisconte, MG
机构
[1] Univ Ferrara, Dipartimento Med Clin & Sperimentale Pediat, Pediat Clin, I-44100 Ferrara, Italy
[2] Ctr Thalassemia, Santo Bambino Catania, Italy
[3] Univ Milan, Dipartimento Med, Milan, Italy
[4] Osped S Eugenio, Day Hosp Thalassemia, Rome, Italy
[5] Osped Cervello, Div Ematol 2, Palermo, Italy
[6] Univ Cagliari, Sez Talassemici Adulti, Dipartimento Sci Med, I-09124 Cagliari, Italy
[7] Osped Galliera, Div Pediat, Genoa, Italy
[8] Univ Turin, Dipartimento Pediat, Turin, Italy
[9] Ctr Studio Microcitemia, Cosenza, Italy
关键词
hepatocellular carcinoma; thalassaemia; hepatitis C; cirrhosis; iron overload;
D O I
10.1046/j.1365-2141.2003.04732.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hepatocellular carcinoma (HCC) frequently complicates hepatic cirrhosis secondary to viral infection or iron overload. Therefore, patients affected by thalassaemia syndromes have a theoretically high risk of developing the tumour. We collected data on patients attending Italian centres for the treatment of thalassaemia. Twenty-two cases of HCC were identified; 15 were male. At diagnosis, the mean age was 45 +/- 11 years and the mean serum ferritin was 1764 +/- 1448 mug/l. Eighty-six percent had been infected by hepatitis C virus. Nineteen of 22 cases were diagnosed after 1993, suggesting that this problem is becoming more frequent with the aging population of thalassaemia patients.
引用
收藏
页码:114 / 117
页数:4
相关论文
共 12 条
[1]   Survival and disease complications in thalassemia major [J].
Borgna-Pignatti, C ;
Rugolotto, S ;
De Stefano, P ;
Piga, A ;
Di Gregorio, F ;
Gamberini, MR ;
Sabato, V ;
Melevendi, C ;
Cappellini, MD ;
Verlato, G .
COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 :227-231
[2]   HEPATOCELLULAR-CARCINOMA IN THALASSEMIA MAJOR [J].
BORGNAPIGNATTI, C ;
DESTEFANO, P ;
SESSA, F ;
AVATO, F .
MEDICAL AND PEDIATRIC ONCOLOGY, 1986, 14 (06) :327-328
[3]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[4]   Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C [J].
Minola, E ;
Prati, D ;
Suter, F ;
Maggiolo, F ;
Caprioli, F ;
Sonzogni, A ;
Fraquelli, M ;
Paggi, S ;
Conte, D .
BLOOD, 2002, 99 (12) :4588-4591
[5]   Survival in β-thalassaemia major in the UK:: data from the UK thalassaemia register [J].
Modell, B ;
Khan, M ;
Darlison, M .
LANCET, 2000, 355 (9220) :2051-2052
[6]   Long-term survival in patients with hereditary hemochromatosis [J].
Niederau, C ;
Fischer, R ;
Purschel, A ;
Stremmel, W ;
Haussinger, D ;
Strohmeyer, G .
GASTROENTEROLOGY, 1996, 110 (04) :1107-1119
[7]   RANDOMIZED TRIAL OF EFFECTS OF INTERFERON-ALPHA ON INCIDENCE OF HEPATOCELLULAR-CARCINOMA IN CHRONIC ACTIVE HEPATITIS-C WITH CIRRHOSIS [J].
NISHIGUCHI, S ;
KUROKI, T ;
NAKATANI, S ;
MORIMOTO, H ;
TAKEDA, T ;
NAKAJIMA, S ;
SHIOMI, S ;
SEKI, S ;
KOBAYASHI, K ;
OTANI, S .
LANCET, 1995, 346 (8982) :1051-1055
[8]   Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major [J].
Prati, D .
VOX SANGUINIS, 2000, 79 (03) :129-137
[9]  
Ryder S. D., 2003, Gut, V52, P1
[10]   CLINICAL OUTCOMES AFTER TRANSFUSION-ASSOCIATED HEPATITIS-C [J].
TONG, MJ ;
ELFARRA, NS ;
REIKES, AR ;
CO, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (22) :1463-1466